MedTrace Logo

Etanercept (Enbrel) in Undifferentiated Spondyloarthritis

NCT01289730 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2011-02-04

No results posted yet for this study

Summary

The study has the aim to investigate the efficacy and safety of etanercept in patients with active undifferentiated spondyloarthritis (uSpA) over the period of 520 weeks.

Conditions

  • Spondyloarthritis

Interventions

DRUG

Etanercept

Etanercept 25 mg subcutaneously twice a week

Sponsors & Collaborators

  • Rheumazentrum Ruhrgebiet

    collaborator OTHER

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Joachim Sieper, Prof. Dr. · Charite University, Berlin, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2003-09-30
Completion
2012-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289730 on ClinicalTrials.gov